Thyroid diseases and alterations (such as hypothyroidism, thyrotoxicosis, painless thyroiditis, or even thyroid storm [11]) are reported in 1–6% of patients treated with anti–CTLA–4–antibodies [48], representing the second most frequent kind of irAEs [11,49]. Here, CTLA4 is linked to thyrotoxicosis.